Omega-3 Fatty Acid Dosing Recommendations

General Population Recommendations

The American Heart Association recommends all adults consume fatty fish at least two servings per week, which provides approximately 400-500 mg/day of EPA+DHA combined, for general cardiovascular health 1, 2
For those who don't eat fish regularly, 500 mg EPA+DHA daily from supplements is recommended for baseline cardiovascular protection 2
Plant-based omega-3 sources require 1.5-3 grams daily but are less potent than marine-sourced EPA+DHA 3, 2

For documented coronary heart disease, take 1 gram (850-1,000 mg) EPA+DHA daily, which reduces cardiovascular events by 45% for sudden death and 15% for total death, nonfatal MI, and stroke, with evidence strength Grade A based on large randomized trials 1, 2
For hypertriglyceridemia, take 2-4 grams EPA+DHA daily, which lowers triglycerides by 20-40%, under physician supervision 3, 2
Doses above 3 grams require physician supervision due to theoretical bleeding risk, though no increased bleeding has been documented up to 5 grams daily 2

Up to 5 grams EPA+DHA daily is safe for long-term use without increased bleeding risk, and EPA alone up to 1.8 grams daily has been specifically validated as safe 2
No increased bleeding occurs even with concurrent antiplatelet or anticoagulant therapy at doses up to 4 grams daily 2
Doses >3 grams daily require physician supervision, and high-dose supplementation (≥4 grams daily) increases atrial fibrillation risk by 25% 3, 2

For elderly patients with established cardiovascular disease, 850-1,000 mg EPA+DHA daily is recommended, and for cognitive health in those with APOE e4/e4 genotype, consider 1,500-2,000 mg EPA+DHA daily with higher EPA:DHA ratio (2:1) 2
For pregnant/nursing women, follow general population recommendations for fish consumption (twice weekly) and be cautious about mercury exposure from certain fish species 2
For patients in polluted urban environments, 500-1,000 mg EPA+DHA daily is recommended for those without cardiovascular disease in moderately polluted areas, and 1-3 grams EPA+DHA daily for those with established cardiovascular disease in heavily polluted areas 4

Using omega-3 supplements for diabetes management has no benefit for glycemic control or primary cardiovascular prevention in diabetes, with evidence strength Grade A 3, 1
No increased bleeding risk exists up to 5 grams daily, even with anticoagulants, and high-dose omega-3s (≥4 grams) increase atrial fibrillation risk by 25% 2

The American Diabetes Association states that evidence is insufficient to recommend omega‑3 supplements for people with diabetes for prevention or treatment of cardiovascular events, despite diabetes being a high‑risk condition. Evidence level: insufficient (no benefit demonstrated) 5
The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends against omega‑3 fatty‑acid supplements in individuals with dementia for correcting cognitive impairment, citing high‑grade evidence from systematic reviews that show no benefit. Evidence level: high‑grade systematic review 6
The Surviving Sepsis Campaign advises against using omega‑3 fatty acids as an immune supplement in critically ill patients, indicating that supplementation provides no benefit in acute illness. Evidence level: guideline recommendation based on clinical trial data 7

Severe hypertriglyceridemia (≥ 500 mg/dL): For patients with triglycerides ≥ 500 mg/dL, prescribe 2–4 g EPA + DHA daily under physician supervision. This recommendation is attributed to the Surviving Sepsis Campaign guidance, which discourages routine supplementation but acknowledges that targeted, prescription‑grade products may be used in specific metabolic contexts. Evidence level: guideline‑based recommendation 7
Primary‑prevention subgroups (Black adults or low fish intake): For patients who are Black or who consume < 1.5 servings of fatty fish per week, consider 500–1,000 mg EPA + DHA daily for primary cardiovascular prevention. This suggestion follows the same Surviving Sepsis guideline framework, emphasizing selective use rather than universal supplementation. Evidence level: guideline‑based recommendation 7

Current evidence does not support omega‑3 supplementation for glycemic control in diabetes, cognitive improvement in dementia, or general disease prevention in other chronic conditions. Both the ESPEN and American Diabetes Association guidelines conclude that supplementation offers no demonstrable advantage in these populations. Evidence level: insufficient/negative (systematic reviews and guideline assessments) [6][5]